Dyne Therapeutics (NasdaqGS:DYN) has initiated the Phase 3 Harmonia trial of DYNE-101 in myotonic dystrophy type 1, following alignment with the FDA on the study design. The Harmonia trial is a ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

For decades, scientists have recognized that human immunodeficiency virus (HIV) is a formidable viral pathogen. After years of probing work and extensive experimentation, a Yale research team has ...